Lupin Ltd Share Price – NSE  /  BSE

Pharmaceuticals, Mid Cap

Lupin has allotted 57,384 equity shares under ESOP on 26 July 2024.

In view of the above, the issued and paid-up capital of the Company has been increased to Rs 91,20,32,538 consisting of 45,60,16,269 equity shares of Rs 2/- each.

Powered by Capital Market - Live News

Lupin will hold a meeting of the Board of Directors of the Company on 6 August 2024.

Powered by Capital Market - Live News

Lupin announced today that it has divested its U.S. Commercial Women's Health Specialty Business to Evofem Biosciences, Inc. (OTCQB: EVFM) (Evofem), a U.S. biopharmaceutical company focused exclusively on Women's Health.

Lupin's U.S. Commercial Women's Health Specialty Business is primarily focused on commercializing SOLOSEC® (secnidazole) 2g oral granules. This FDA-approved single-dose antimicrobial agent provides a complete course of therapy for the treatment of bacterial vaginosis (BV) and trichomoniasis, two common sexual health infections.

Under the terms of the deal, Lupin can receive a potential total consideration of up to USD 84 million based on future contingent milestones.

Powered by Capital Market - Live News

The said report classified under Voluntary Action Indicated (VAI) status. The facility was inspected from 8 to 12 April 2024.

Nilesh Gupta, managing director, Lupin, said, “We are pleased to receive the EIR for Dabhasa from the U.S. FDA. This achievement is in line with our continued focus and commitment to maintaining the highest standards of quality and compliance in all aspects of our operations. This reaffirms our pursuit of delivering high-quality, affordable healthcare solutions to our patients globally.”

Mumbai-based Lupin is an innovation-led transnational pharmaceutical company. It develops and commercializes a wide range of branded and generic formulations, biotechnology products, and APIs in over 100 markets in the U.S., India, South Africa, and across the Asia Pacific (APAC), Latin America (LATAM), Europe, and Middle East regions.

The company’s consolidated net profit tumbled 41.38% to Rs 359.43 crore on 3.64% decline in revenue from operations to Rs 4,895.11 crore in Q4 FY24 over Q4 FY23.

The scrip declined 1.09% to ended at Rs 1,797.10 in the BSE.

Powered by Capital Market - Live News